Diabetes downregulates renal adenosine A2A receptors in an experimental model of hypertension.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
12
2018
accepted:
14
05
2019
entrez:
1
6
2019
pubmed:
1
6
2019
medline:
6
2
2020
Statut:
epublish
Résumé
Studies on diabetic nephropathy rarely take into account that the co-existence of diabetes and hypertension is frequent and further aggravates the prognosis of renal dysfunction. Adenosine can activate four subtypes of adenosine receptors (A1, A2A, A2B and A3) and has been implicated in diabetic nephropathy. However, it is not known if, in hypertensive conditions, diabetes alters the presence/distribution profile of renal adenosine receptors. The aim of this work was to describe the presence/distribution profile of the four adenosine receptors in six renal structures (superficial/deep glomeruli, proximal/distal tubules, loop of Henle, collecting tubule) of the hypertensive kidney and to evaluate whether it is altered by diabetes. Immunoreactivities against the adenosine receptors were analyzed in six renal structures from spontaneously hypertensive rats (SHR, the control group) and from SHR rats with diabetes induced by streptozotocyin (SHR-STZ group). Data showed, for the first time, that all adenosine receptors were present in the kidney of SHR rats, although the distribution pattern was specific for each adenosine receptor subtype. Also, induction of diabetes in the SHR was associated with downregulation of adenosine A2A receptors, which might be relevant for the development of hypertensive diabetic nephropathy. This study highlights the adenosine A2A receptors as a potential target to explore to prevent and/or treat early diabetes-induced hyperfiltration, at least in hypertensive conditions.
Identifiants
pubmed: 31150459
doi: 10.1371/journal.pone.0217552
pii: PONE-D-18-35029
pmc: PMC6544351
doi:
Substances chimiques
Receptor, Adenosine A2A
0
Streptozocin
5W494URQ81
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0217552Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Pharmacol Exp Ther. 2000 Feb;292(2):752-60
pubmed: 10640315
Hemodial Int. 2014 Oct;18(4):730-9
pubmed: 24641780
Hypertension. 1995 Dec;26(6 Pt 2):1181-5
pubmed: 7498992
Heliyon. 2018 Jun 29;4(6):e00669
pubmed: 30003163
Comput Methods Programs Biomed. 2018 Mar;155:179-187
pubmed: 29512497
J Biol Chem. 2010 Dec 17;285(51):40104-13
pubmed: 20940302
Ups J Med Sci. 2001;106(3):175-82
pubmed: 12166509
Life Sci. 2009 May 22;84(21-22):772-8
pubmed: 19324061
Am J Physiol. 1992 Dec;263(6 Pt 2):F991-5
pubmed: 1481890
Physiol Rev. 1998 Jul;78(3):723-44
pubmed: 9674692
Curr Drug Targets. 2013 Apr;14(4):490-6
pubmed: 23316933
Biochem Biophys Res Commun. 2008 Feb 1;366(1):180-5
pubmed: 18060864
Diabetologia. 2009 Apr;52(4):691-7
pubmed: 19198800
Histochem Cell Biol. 2019 May;151(5):407-418
pubmed: 30357508
Am J Pathol. 2005 Aug;167(2):315-25
pubmed: 16049319
J Am Soc Nephrol. 2008 Apr;19(4):722-30
pubmed: 18256360
Handb Exp Pharmacol. 2009;(193):443-70
pubmed: 19639291
Kidney Int. 2004 Apr;65(4):1180-90
pubmed: 15086457
Ups J Med Sci. 2014 Mar;119(1):10-8
pubmed: 24195577
Histochem Cell Biol. 2018 Mar;149(3):209-218
pubmed: 29356964
Int J Biochem Cell Biol. 2005 Jan;37(1):155-65
pubmed: 15381158
J Pharmacol Exp Ther. 1985 Mar;232(3):589-94
pubmed: 2983063
Diabetes Metab Res Rev. 2004 Nov-Dec;20(6):452-9
pubmed: 15386825
Am J Physiol Renal Physiol. 2001 Dec;281(6):F1141-7
pubmed: 11704566
Lab Invest. 2013 Jan;93(1):135-44
pubmed: 23069939
J Physiol Pharmacol. 2003 Mar;54(1):109-20
pubmed: 12674223
J Am Soc Nephrol. 2011 May;22(5):890-901
pubmed: 21511827
Anal Biochem. 2006 Oct 1;357(1):137-43
pubmed: 16914112
J Am Soc Nephrol. 1999 Apr;10(4):714-20
pubmed: 10203354
Kidney Int. 2002 Apr;61(4):1276-85
pubmed: 11918734
J Membr Biol. 2000 Nov 15;178(2):103-13
pubmed: 11083899
Life Sci. 2007 Mar 20;80(15):1364-72
pubmed: 17331548
Blood. 2008 Feb 15;111(4):2024-35
pubmed: 18056839
Hypertens Res. 2003 Apr;26(4):339-47
pubmed: 12733703
J Am Soc Nephrol. 2007 Oct;18(10):2715-23
pubmed: 17855643
J Endocrinol. 2006 Oct;191(1):147-57
pubmed: 17065398
Am J Physiol. 1996 May;270(5 Pt 2):F798-805
pubmed: 8928841
Am J Physiol Renal Physiol. 2013 Mar 1;304(5):F614-22
pubmed: 23283998
Hypertension. 2006 Oct;48(4):519-26
pubmed: 16952978
Hypertension. 2005 Sep;46(3):628-34
pubmed: 16103269
Physiol Rev. 2006 Jul;86(3):901-40
pubmed: 16816141
Diabetes Metab Syndr Obes. 2013 Sep 17;6:327-38
pubmed: 24082791
Microsc Res Tech. 2008 Oct;71(10):703-9
pubmed: 18570336
Am J Pathol. 2013 Nov;183(5):1488-1497
pubmed: 24001475
Kidney Int. 1989 Jun;35(6):1300-5
pubmed: 2770110
Am J Physiol Renal Physiol. 2006 Apr;290(4):F828-37
pubmed: 16332931
J Pharmacol Pharmacother. 2010 Jul;1(2):94-9
pubmed: 21350617
Kidney Int. 2009 Apr;75(8):769-71
pubmed: 19337216
Ann Clin Lab Sci. 2016 Jul;46(4):339-45
pubmed: 27466291
Biochem Pharmacol. 2001 Jan 15;61(2):237-44
pubmed: 11163338
FEBS Lett. 2009 Oct 6;583(19):3192-8
pubmed: 19737558
Life Sci. 2014 Jul 17;108(2):71-9
pubmed: 24862547
Lancet. 2013 Jul 20;382(9888):260-72
pubmed: 23727169
Jpn Circ J. 1963 Mar;27:282-93
pubmed: 13939773
Annu Rev Pharmacol Toxicol. 1991;31:1-35
pubmed: 2064369
J Pharmacol Exp Ther. 2005 Dec;315(3):1150-7
pubmed: 16120812
PLoS One. 2016 Jan 25;11(1):e0147430
pubmed: 26808537
Can J Physiol Pharmacol. 2000 May;78(5):428-32
pubmed: 10841439
Nat Clin Pract Endocrinol Metab. 2008 Aug;4(8):444-52
pubmed: 18607402
J Am Soc Nephrol. 2008 Jan;19(1):59-68
pubmed: 18045850
Circ Res. 1981 Mar;48(3):309-19
pubmed: 7460205
Hypertension. 2010 May;55(5):1123-8
pubmed: 20308611